Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

SANDOZ PROPOSED BIOSIMILARS ADALIMUMAB AND INFLIXIMAB ACCEPTED FOR REGULATORY REVIEW BY THE EUROPEAN MEDICINES AGENCY

Sandoz, a Novartis division, and a pioneer and global leader in Biosimilars, announced today that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Applications for biosimilars to Humira®* (adalimumab) and Remicade®** (infliximab), both of which are used to treat immunological diseases. Biosimilars are biological medicines that have been developed to be highly similar […]



This post first appeared on Global Banking And Finance Review Magazine – Fin, please read the originial post: here

Share the post

SANDOZ PROPOSED BIOSIMILARS ADALIMUMAB AND INFLIXIMAB ACCEPTED FOR REGULATORY REVIEW BY THE EUROPEAN MEDICINES AGENCY

×

Subscribe to Global Banking And Finance Review Magazine – Fin

Get updates delivered right to your inbox!

Thank you for your subscription

×